A phase II dose-ranging study of mirabegron in patients with overactive bladder

@inproceedings{Chapple2013API,
  title={A phase II dose-ranging study of mirabegron in patients with overactive bladder},
  author={Christopher R Chapple and Vladim{\'i}r Dvoř{\'a}k and Pjotr Radziszewski and Philip E. V. Van Kerrebroeck and Jean-Jacques Wyndaele and Brigitte Bosman and Peter J Boerrigter and Ted Drogendijk and A. J. M. De Ridder and Ingrid Van Der Putten-Slob and Osamu Yamaguchi},
  booktitle={International Urogynecology Journal},
  year={2013}
}
Mirabegron is a potent and selective β3-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Patients completed a single-blinded, 2-week placebo run-in period followed by 12 weeks of randomized (n = 928) double-blinded treatment with mirabegron oral controlled absorption system (OCAS) 25, 50, 100, or 200 mg once-daily (QD), placebo or tolterodine extended release (ER) 4 mg QD. The primary endpoint was change… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
34 Extracted Citations
20 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 34 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…